Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Sang Yu

Showing results (161-170 of 349) with videos related to

Pageof 35
Sort By:
Clinical and Translational Science|March 4, 2024
Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjectsHeejae Won, Deok Yong Yoon, Sangmi Lee, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatographyJoo Youn Cho, Hyo Bum Seo, Kyung Sang Yu, et al.
Clinical Drug Investigation|December 14, 2011
Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective reviewSo-Hee Lee, Hye-Ryun Kang, Jae-Woo Jung, et al.
Clinical Therapeutics|November 1, 2011
Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover studyKwang-Hee Shin, Sung Eun Kim, Seo Hyun Yoon, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2023
Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjectsInyoung Hwang, Sang Chun Ji, Jaeseong Oh, et al.
Clinical and Translational Science|March 3, 2025
Exploration of Using an Open-Source Large Language Model for Analyzing Trial Information: A Case Study of Clinical Trials With Decentralized ElementsKi Young Huh, Ildae Song, Yoonjin Kim, et al.
Drug Design, Development and Therapy|January 29, 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteersSeonghae Yoon, Howard Lee, Tae-Eun Kim, et al.
Journal of Clinical Pharmacology|December 30, 2015
Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly SubjectsKyungho Jang, Hyewon Chung, Jang-Soo Yoon, et al.
Drug Design, Development and Therapy|May 6, 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP<sup>®</sup>) Biosimilar, to Those of NESP<sup>®</sup> After a Single Subcutaneous or Intravenous Administration to Healthy SubjectsInseung Jeon, Jaeseong Oh, Yu-Kyung Kwon, et al.
Diabetes Research and Clinical Practice|July 30, 2021
Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acidsYujin Lee, Andrew HyoungJin Kim, Eunwoo Kim, et al.
Pageof 35

Showing results (161-170 of 349) with videos related to

Sort By:
Pageof 35
Clinical and Translational Science|March 4, 2024
Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjectsHeejae Won, Deok Yong Yoon, Sangmi Lee, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 31, 2002
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatographyJoo Youn Cho, Hyo Bum Seo, Kyung Sang Yu, et al.
Clinical Drug Investigation|December 14, 2011
Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective reviewSo-Hee Lee, Hye-Ryun Kang, Jae-Woo Jung, et al.
Clinical Therapeutics|November 1, 2011
Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover studyKwang-Hee Shin, Sung Eun Kim, Seo Hyun Yoon, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2023
Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjectsInyoung Hwang, Sang Chun Ji, Jaeseong Oh, et al.
Clinical and Translational Science|March 3, 2025
Exploration of Using an Open-Source Large Language Model for Analyzing Trial Information: A Case Study of Clinical Trials With Decentralized ElementsKi Young Huh, Ildae Song, Yoonjin Kim, et al.
Drug Design, Development and Therapy|January 29, 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteersSeonghae Yoon, Howard Lee, Tae-Eun Kim, et al.
Journal of Clinical Pharmacology|December 30, 2015
Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly SubjectsKyungho Jang, Hyewon Chung, Jang-Soo Yoon, et al.
Drug Design, Development and Therapy|May 6, 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP<sup>®</sup>) Biosimilar, to Those of NESP<sup>®</sup> After a Single Subcutaneous or Intravenous Administration to Healthy SubjectsInseung Jeon, Jaeseong Oh, Yu-Kyung Kwon, et al.
Diabetes Research and Clinical Practice|July 30, 2021
Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acidsYujin Lee, Andrew HyoungJin Kim, Eunwoo Kim, et al.
Pageof 35